Telmisartan

Generic Name: Telmisartan

Brand Names: Actelsar Hct, Micardis, Micardis-hct, Pritor, Twynsta, Tolura, Kinzalmono (previously Telmisartan Boehringer Ingelheim Pharma KG), Telmisartan Teva Pharma, Telmisartan Actavis

Drug Type: Small Molecule

Chemical Formula: C_₃₃H_₃₀N_₄O_₂

CAS Number: 144701-48-4

Unique Ingredient Identifier: U5SYW473RQ

Background: Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. Generally, angiotensin II receptor blockers (ARBs) such as telmisartan bind to the angiotensin II type 1 (AT1) receptors with high affinity, causing inhibition of the action of angiotensin II on vascular smooth muscle, ultimately leading to a reduction in arter...

Indication: Used alone or in combination with other classes of antihypertensives for the treatment of hypertension. Also used in the treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes mellitus, as well as the treatment of congestive heart failure (only in patients who cannot tolerate ACE inhibitors).

Associated Conditions: Cardiovascular Events, Diabetic Nephropathy, Heart Failure, Hypertension

Associated Therapies: -

Clinical Trials

Analysis of Telmisartan Administered With Antiretroviral Therapy (ART) in Patients With Acute HIV Infection

Phase 1

Completed

Conditions: Acute HIV Infection
HIV Infections

Interventions: Drug: Telmisartan

First Posted Date: 2014-06-23

Last Posted Date: 2020-03-09

Lead Sponsor: Yale University

Target Recruit Count: 21

Registration Number: NCT02170246

Locations: 🇹🇭
Chulalongkorn University Hospital, Bangkok, Thailand
🇹🇭
Thai Red Cross AIDS Research Centre, Bangkok, Thailand

Drug-drug Interaction Study (Telmisartan, Amlodipine, Chlorthalidone)

Phase 1

Completed

Conditions: Hypertension

Interventions: Drug: Telmisartan
Drug: Amlodipine
Drug: Chlorthalidone

First Posted Date: 2014-06-02

Last Posted Date: 2014-11-19

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 66

Registration Number: NCT02152969

Locations: 🇰🇷
The Catholic University of Korea Seoul St.Mary's Hospital, Seoul, Korea, Republic of

Telmisartan vs. Perindopril in Mild-Moderate Alzheimer's Disease Patients

Phase 2

Conditions: Alzheimer's Disease

Interventions: Drug: Perindopril
Drug: Telmisartan

First Posted Date: 2014-03-12

Last Posted Date: 2022-05-04

Lead Sponsor: Sunnybrook Health Sciences Centre

Target Recruit Count: 150

Registration Number: NCT02085265

Locations: 🇨🇦
Hamilton General Hospital, Hamilton, Ontario, Canada
🇨🇦
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
🇨🇦
Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada

and more 7 locations

A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R

Phase 4

Completed

Conditions: Essential Hypertension Complicated by Type 2 Diabetes Mellitus

Interventions: Drug: Azilsartan
Drug: Telmisartan

First Posted Date: 2014-03-06

Last Posted Date: 2017-08-02

Lead Sponsor: Takeda

Target Recruit Count: 33

Registration Number: NCT02079805

Comparative Study of the Effects of Telmisartan and Nebivolol

Phase 4

Conditions: Hypertension

Interventions: Drug: NEBIVOLOL
Drug: TELMISARTAN

First Posted Date: 2014-02-07

Last Posted Date: 2014-02-07

Lead Sponsor: Aristotle University Of Thessaloniki

Target Recruit Count: 80

Registration Number: NCT02057328

Locations: 🇬🇷
Hypertension-ABPM Center 3rd department of Internal Medicine, Thessaloniki, Greece

Non-invasive Haemodynamic Assessment in Hypertension

Not Applicable

Completed

Conditions: Arterial Hypertension

Interventions: Drug: lisinopril
Drug: Telmisartan
Drug: Nebivolol
Drug: Indapamide/hydrochlorothiazide
Drug: Amlodipine

First Posted Date: 2013-11-27

Last Posted Date: 2018-03-13

Lead Sponsor: Military Institute od Medicine National Research Institute

Target Recruit Count: 144

Registration Number: NCT01996085

Locations: 🇵🇱
Military Institute of Medicine, Warsaw, Mazovia, Poland

Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)

Phase 2

Completed

Conditions: HIV-1 Infection

Interventions: Drug: Telmisartan

First Posted Date: 2013-08-27

Last Posted Date: 2021-08-03

Lead Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Target Recruit Count: 58

Registration Number: NCT01928927

Locations: 🇺🇸
UCLA CARE Center CRS (601), Los Angeles, California, United States
🇺🇸
University of Rochester Adult HIV Therapeutic Strategies Network CRS (31787), Rochester, New York, United States
🇺🇸
Washington U CRS (2101), Saint Louis, Missouri, United States

and more 9 locations

Efficacy and Safety Study of YH16410 Versus Rosuvastatin and Telmisartan Monotherapies in Patients With Hypertension and Hyperlipidemia

Phase 3

Completed

Conditions: Hyperlipidemia
Hypertension

Interventions: Drug: YH16410 placebo
Drug: YH16410
Drug: Rosuvastatin
Drug: Telmisartan
Drug: Rosuvastatin placebo
Drug: Telmisartan placebo

First Posted Date: 2013-08-02

Last Posted Date: 2014-07-08

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 210

Registration Number: NCT01914432

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

HALT Progression of Polycystic Kidney Disease Study B

Phase 3

Completed

Conditions: Kidney, Polycystic

Interventions: Drug: Lisinopril
Drug: Placebo
Drug: Telmisartan

First Posted Date: 2013-06-25

Last Posted Date: 2020-04-22

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 486

Registration Number: NCT01885559

Locations: 🇺🇸
University of Colorado Health Sciences Center, Aurora, Colorado, United States
🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸
Tufts University-New England Medical Center, Boston, Massachusetts, United States

and more 4 locations

HIGH Altitude CArdiovascular REsearch in the ANDES

Phase 4

Completed

Conditions: Hypertension
High Altitude

Interventions: Drug: placebo
Drug: Telmisartan
Drug: Nifedipine

First Posted Date: 2013-04-12

Last Posted Date: 2013-04-12

Lead Sponsor: Istituto Auxologico Italiano

Target Recruit Count: 100

Registration Number: NCT01830530

Locations: 🇵🇪
Universidad Peruana Cayetano Heredia, Lima, Peru

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy